Dear Nicox Shareholder,
You may have seen the announcement (attached) of our increase of capital dedicated to a specific category of investors and you might wonder why we did it just on the back of the very disappointing news of a further, unexpected delay on the decision regarding the approval of VYZULTA.
We at Nicox, the Board and the management,
- First approved US NDA for Nicox
- First topical ocular formulation of the antihistamine cetirizine
- U.S. patent protection until at least 2030
- Partnering discussions underway for U.S. commercialization rights
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that the U.S.